Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model

Nucleolin (NCL) is highly expressed in several types of cancer and represents an interesting therapeutic target. It is expressed at the plasma membrane of tumor cells, a property which is being used as a marker for several human cancer including glioblastoma. In this study we investigated targeting NCL as a new therapeutic strategy for the treatment of this pathology. To explore this possibility, we studied the effect of an antagonist of NCL, the multivalent pseudopeptide N6L using primary culture of human glioblastoma cells. In this system, N6L inhibits cell growth with different sensitivity depending to NCL localization. Cell cycle analysis indicated that N6L-induced growth reduction was due to a block of the G1/S transition with down-regulation of the expression of cyclin D1 and B2. By monitoring autophagy markers such as p62 and LC3II, we demonstrate that autophagy is enhanced after N6L treatment. In addition, N6L-treatment of mice bearing tumor decreased in vivo tumor growth in orthotopic brain tumor model and increase mice survival. The results obtained indicated an anti-proliferative and pro-autophagic effect of N6L and point towards its possible use as adjuvant agent to the standard therapeutic protocols presently utilized for glioblastoma.

[1]  P. Bouvet,et al.  The roles of nucleolin subcellular localization in cancer. , 2015, Biochimie.

[2]  Seamus J. Martin,et al.  Autophagy in malignant transformation and cancer progression , 2015, The EMBO journal.

[3]  J. Lippincott-Schwartz,et al.  Deacetylation of nuclear LC3 drives autophagy initiation under starvation. , 2015, Molecular cell.

[4]  C. Cobbs,et al.  Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy , 2015, Oncotarget.

[5]  Y. Kloog,et al.  Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma , 2014, Oncotarget.

[6]  E. Papadimitriou,et al.  Cell surface nucleolin as a target for anti-cancer therapies. , 2014, Recent patents on anti-cancer drug discovery.

[7]  A. Giordano,et al.  Glycosilated nucleolin as marker for human gliomas , 2012, Journal of cellular biochemistry.

[8]  A. Hovanessian,et al.  Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type , 2011, BMC Cancer.

[9]  A. van Dorsselaer,et al.  A simple approach to cancer therapy afforded by multivalent pseudopeptides that target cell-surface nucleoproteins. , 2011, Cancer research.

[10]  Y. Eishi,et al.  Autophagy-deficient mice develop multiple liver tumors. , 2011, Genes & development.

[11]  P. Bates,et al.  Oncogenic synergism between ErbB1, nucleolin, and mutant Ras. , 2011, Cancer research.

[12]  Gyan Bhanot,et al.  Autophagy Suppresses Tumorigenesis through Elimination of p62 , 2009, Cell.

[13]  John O Trent,et al.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. , 2009, Experimental and molecular pathology.

[14]  P. Albanese,et al.  Suppression of Tumor Growth and Angiogenesis by a Specific Antagonist of the Cell-Surface Expressed Nucleolin , 2008, PloS one.

[15]  R. Pinkas-Kramarski,et al.  Identification of Nucleolin as New ErbB Receptors- Interacting Protein , 2008, PloS one.

[16]  Nektarios Tavernarakis,et al.  Regulation of autophagy by cytoplasmic p53 , 2008, Nature Cell Biology.

[17]  J. Flores,et al.  The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. , 2008, Cancer cell.

[18]  Hubing Shi,et al.  Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. , 2007, Blood.

[19]  Hubing Shi,et al.  The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. , 2006, Blood.

[20]  Terje Johansen,et al.  p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death , 2005, The Journal of cell biology.

[21]  J. Courty,et al.  Pleiotrophin inhibits HIV infection by binding the cell surface‐expressed nucleolin , 2005, The FEBS journal.

[22]  M. Westphal,et al.  Glioblastoma and Cerebral Microvascular Endothelial Cell Migration in Response to Tumor-associated Growth Factors , 2003, Neurosurgery.

[23]  M. Hirai,et al.  Nuclear Targeting by the Growth Factor Midkine , 2002, Molecular and Cellular Biology.

[24]  G. Reifenberger,et al.  The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.

[25]  P. Hofschneider,et al.  Characterization of a 100-kilodalton binding protein for the six serotypes of coxsackie B viruses , 1995, Journal of virology.

[26]  H. Kleinman,et al.  A 110‐kD nuclear shuttling protein, nucleolin, binds to the neurite‐promoting IKVAV site of laminin‐1 , 1995, Journal of neuroscience research.

[27]  D. Treré,et al.  Quantitative changes of the two major AgNOR proteins, nucleolin and protein B23, related to stimulation of rDNA transcription. , 1995, Experimental cell research.

[28]  O D Laerum,et al.  Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. , 1990, Cancer research.

[29]  Quanyin Hu,et al.  F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery. , 2013, Biomaterials.